公司概述
Tempus AI, Inc. operates as a healthcare technology company in the United States, offering the Tempus platform which facilitates closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data. The company functions within the Healthcare sector and specifically within the Health Information Services industry, positioning itself at the intersection of medical practice and advanced data analytics. Tempus AI maintains a significant market presence with a market capitalization of $8.52B and an annual revenue of $1.27B, supported by a workforce of 3,800 employees. These valuation and revenue figures indicate that the market assigns a substantial premium to the company's proprietary data infrastructure and platform capabilities, suggesting strong investor confidence in its long-term potential despite current profitability challenges.
财务健康
Tempus AI reported revenue of $1.27B over the trailing twelve months, yet recorded a net income of -$245,028,000 and an EBITDA of -$171,512,992, revealing a cost structure where expenses significantly outweigh earnings before interest, taxes, and depreciation. The company generated free cash flow of -$112,498,872, which indicates a heavy reliance on external capital sources to fund operations and expansion rather than organic cash generation. Margin analysis shows a gross margin of 62.7%, suggesting efficient production or service delivery costs, while the operating margin stands at -16.7% and the profit margin is -19.3%, highlighting substantial operational and general administrative expenses that erode pre-tax profits. On the balance sheet, the company holds $755.00M in cash against $1.33B in debt, resulting in a debt-to-equity ratio of 270.11, which characterizes a highly leveraged position rather than a conservative one. Despite the high leverage, the current ratio of 3.13 indicates robust short-term liquidity, as current assets are more than three times current liabilities. Furthermore, the return on equity is -89.5% and the return on assets is -9.7%, metrics that reveal management has yet to generate positive returns on shareholder capital or total assets during this reporting period.
估值评估
Valuation metrics for Tempus AI reflect its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -760.61, implying that the market is pricing the stock based on future earnings expectations that are not yet realized in current financial statements. The price-to-book ratio is 17.22, indicating that the market values the company at a significant premium over its book value, likely due to the intangible value of its data repository and platform technology. Alternative valuation multiples such as a price-to-sales ratio of 6.70 and an EV/EBITDA of -52.85 further suggest that traditional earnings-based valuation models are inapplicable, and investors are relying on revenue growth and strategic positioning to justify the current price. The stock has traded within a 52-week range between a low of $36.22 and a high of $104.32, with the current price situated in the upper half of this historical range relative to the low, though specific percentage distance requires real-time price input not provided in the static facts. The beta value is listed as N/A, meaning standard volatility metrics relative to the broader market cannot be quantified from the available data, preventing a direct comparison of price sensitivity to market movements.
Growth & Income
Tempus AI demonstrated impressive revenue growth of 83.0% year-over-year, while earnings growth is listed as N/A due to the company's ongoing net losses, implying that top-line expansion is currently the primary driver of business progress rather than profitability scaling. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which signifies that all available earnings, when positive in the future, or existing cash reserves are being reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is typical for growth-stage biotech and health tech firms that prioritize scaling their platform and acquiring data over returning capital to investors. Overall, the growth and income profile of Tempus AI is characterized by rapid revenue expansion and zero dividend distribution, reflecting a business model focused on long-term platform monetization and market capture rather than immediate income generation.